Electroencephalographic spectral and coherence analysis of ketamine in rats: Correlation with behavioral effects and pharmacokinetics

Neuropsychobiology

Volumn 63, Issue 4, 2011, Pages 202-218

  Páleníček, Tomáš ^a   Fujáková, Michaela ^a   Brunovský, Martin ^a   Balíková, Marie ^b   Horáček, Jiří ^a   Gorman, Ingmar ^a   Tylš, Filip ^a   Tišlerová, Barbora ^a   Šoš, Peter ^a   Bubeníková Valešová, Věra ^a   Höschl, Cyril ^a   Krajča, Vladimír ^c  

^a NATIONAL INSTITUTE OF MENTAL HEALTH   (Czech Republic)

^b CHARLES UNIVERSITY   (Czech Republic)

^c UNIVERSITY HOSPITAL BULOVKA   (Czech Republic)

Author keywords

Electroencephalography, coherence; Electroencephalography, power spectra; Functional connectivity; Ketamine; Locomotion; Open field; Prepulse inhibition; Schizophrenia; Sensorimotor gating

Indexed keywords

DRUG METABOLITE; KETAMINE; NARKETAN; NORKETAMINE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BEHAVIORAL SCIENCE; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG BRAIN LEVEL; DRUG EFFECT; ELECTROENCEPHALOGRAPHY; LOCOMOTION; MALE; MASS FRAGMENTOGRAPHY; NONHUMAN; OPEN FIELD TEST; POWER ANALYSIS; PREPULSE INHIBITION; PRIORITY JOURNAL; PSYCHOSIS; RAT; SENSORY GATING; SINGLE DRUG DOSE; STARTLE REFLEX;

ACOUSTIC STIMULATION; ANIMALS; BRAIN; BRAIN WAVES; DISEASE MODELS, ANIMAL; DOSE-RESPONSE RELATIONSHIP, DRUG; ELECTROENCEPHALOGRAPHY; KETAMINE; LOCOMOTION; MALE; PSYCHOTIC DISORDERS; RATS; RATS, WISTAR; SENSORY GATING;

EID: 79952716353     PISSN: 0302282X     EISSN: None     Source Type: Journal    
DOI: 10.1159/000321803     Document Type: Article

References (90)

1. Goff DC, Coyle JT: The emerging role of glutamate in the pathophysiology and treatment of schizophrenia. Am J Psychiatry 2001; 158: 1367-1377. (Pubitemid 32847232)
2. Owen MJ, Williams NM, O'Donovan MC: The molecular genetics of schizophrenia: new findings promise new insights. Mol Psychiatry 2004; 9: 14-27. (Pubitemid 38175078)
3. Olney JW, Newcomer JW, Farber NB: NMDA receptor hypofunction model of schizophrenia. J Psychiatr Res 1999; 33: 523-533.
4. Bustillo JR, Rowland LM, Mullins P, Jung R, Chen H, Qualls C, Hammond R, Brooks WM, Lauriello J: 1 H-MRS at 4 tesla in minimally treated early schizophrenia. Mol Psychiatry2010; 15: 629-636.
5. Stone JM: Imaging the glutamate system in humans: relevance to drug discovery for schizophrenia. Curr Pharm Des 2009; 15: 2594-2602.
6. Rowland LM, Bustillo JR, Mullins PG, Jung RE, Lenroot R, Landgraf E, Barrow R, Yeo R, Lauriello J, Brooks WM: Effects of ketamine on anterior cingulate glutamate metabolism in healthy humans: a 4-T proton MRS study. Am J Psychiatry 2005; 162: 394-396. (Pubitemid 40216226)
7. Coyle JT, Tsai G: NMDA receptor function, neuroplasticity, and the pathophysiology of schizophrenia. Int Rev Neurobiol 2004; 59: 491-515. (Pubitemid 39752426)
8. Bubeníková-Valesová V, Horácek J, Vrajová M, Höschl C: Models of schizophrenia in humans and animals based on inhibition of NMDA receptors. Neurosci Biobehav Rev 2008; 32: 1014-1023. (Pubitemid 351756510)
9. Seillier A, Giuffrida A: Evaluation of NMDA receptor models of schizophrenia: divergences in the behavioral effects of subchronic PCP and MK-801. Behav Brain Res 2009; 204: 410-415.
10. Kapur S, Seeman P: NMDA receptor antagonists ketamine and PCP have direct effects on the dopamine D 2 and serotonin 5-HT 2 receptors: implications for models of schizophrenia. Mol Psychiatry 2002; 7: 837-844.
11. Seeman P, Ko F, Tallerico T: Dopamine receptor contribution to the action of PCP, LSD and ketamine psychotomimetics. Mol Psychiatry 2005; 10: 877-883. (Pubitemid 43080122)
12. Wolff K, Winstock AR: Ketamine: from medicine to misuse. CNS Drugs 2006; 20: 199-218.
13. Adler CM, Malhotra AK, Elman I, Goldberg T, Egan M, Pickar D, Breier A: Comparison of ketamine-induced thought disorder in healthy volunteers and thought disorder in schizophrenia. Am J Psychiatry 1999; 156: 1646-1649. (Pubitemid 29460002)
14. Vollenweider FX, Leenders KL, Scharfetter C, Antonini A, Maguire P, Missimer J, Angst J: Metabolic hyperfrontality and psychopathology in the ketamine model of psychosis using positron emission tomography (PET) and [ 18 F]fluorodeoxyglucose (FDG). Eur Neuropsychopharmacol 1997; 7: 9-24. (Pubitemid 27139716)
15. Stefanovic A, Brandner B, Klaassen E, Cregg R, Nagaratnam M, Bromley LM, Das RK, Rossell SL, Morgan CJ, Curran HV: Acute and chronic effects of ketamine on semantic priming: modeling schizophrenia? J Clin Psychopharmacol 2009; 29: 124-133.
16. Krystal JH, Karper LP, Seibyl JP, Freeman GK, Delaney R, Bremner JD, Heninger GR, Bowers MB Jr, Charney DS: Subanesthetic effects of the noncompetitive NMDA antagonist, ketamine, in humans: psychotomimetic, perceptual, cognitive, and neuroendocrine responses. Arch Gen Psychiatry 1994; 51: 199-214. (Pubitemid 24081509)
17. Lahti AC, Weiler MA, Tamara Michaelidis BA, Parwani A, Tamminga CA: Effects of ketamine in normal and schizophrenic volunteers. Neuropsychopharmacology 2001; 25: 455-467. (Pubitemid 32830950)
18. Tiedtke PI, Bischoff C, Schmidt WJ: MK- 801-induced stereotypy and its antagonism by neuroleptic drugs. J Neural Transm Gen Sect 1990; 81: 173-182. (Pubitemid 20221240)
19. Carlsson A: Neurocircuitries and neurotransmitter interactions in schizophrenia. Int Clin Psychopharmacol 1995; 10(suppl 3):21-28. (Pubitemid 26054877)
20. Andiné P, Widermark N, Axelsson R, Nyberg G, Olofsson U, Martensson E, Sandberg M: Characterization of MK-801-induced behavior as a putative rat model of psychosis. J Pharmacol Exp Ther 1999; 290: 1393-1408. (Pubitemid 29400285)
21. Swerdlow NR, Geyer MA, Braff DL: Neural circuit regulation of prepulse inhibition of startle in the rat: current knowledge and future challenges. Psychopharmacology (Berl) 2001; 156: 194-215. (Pubitemid 32702213)
22. Koch M: The neurobiology of startle. Prog Neurobiol 1999; 59: 107-128. (Pubitemid 29425879)
23. Vollenweider FX, Geyer MA: A systems model of altered consciousness: integrating natural and drug-induced psychoses. Brain Res Bull 2001; 56: 495-507. (Pubitemid 34031785)
24. Geyer MA, Krebs-Thomson K, Braff DL, Swerdlow NR: Pharmacological studies of prepulse inhibition models of sensorimotor gating deficits in schizophrenia: a decade in review. Psychopharmacology (Berl) 2001; 156: 117-154. (Pubitemid 32702206)
25. Shaw JC, O'Connor KP, Ongley OC: EEG coherence as a measure of cerebral functional organization; in Brazier MB, Petche H (eds): Architectonics of the Cerebral Cortex. New York, Raven, 1978, pp 245-256.
26. Thatcher RW, Krause PJ, Hrybyk M: Cortico- cortical associations and EEG coherence: a two-compartmental model. Electroencephalogr Clin Neurophysiol 1986; 64: 123-143. (Pubitemid 16057727)
27. Boutros NN, Arfken C, Galderisi S, Warrick J, Pratt G, Iacono W: The status of spectral EEG abnormality as a diagnostic test for schizophrenia. Schizophr Res 2008; 99: 225-237.
28. Hughes JR, John ER: Conventional and quantitative electroencephalography in psychiatry. J Neuropsychiatry Clin Neurosci 1999; 11: 190-208. (Pubitemid 29224847)
29. Galderisi S, Mucci A, Volpe U, Boutros N: Evidence-based medicine and electrophysiology in schizophrenia. Clin EEG Neurosci 2009; 40: 62-77.
30. Mann K, Maier W, Franke P, Roschke J, Gansicke M: Intra- and interhemispheric electroencephalogram coherence in siblings discordant for schizophrenia and healthy volunteers. Biol Psychiatry 1997; 42: 655-663. (Pubitemid 27444499)
31. Wada Y, Nanbu Y, Kikuchi M, Koshino Y, Hashimoto T: Aberrant functional organization in schizophrenia: analysis of EEG coherence during rest and photic stimulation in drug-naive patients. Neuropsychobiology 1998; 38: 63-69. (Pubitemid 28414287)
32. Ford JM, Mathalon DH, Whitfield S, Faustman WO, Roth WT: Reduced communication between frontal and temporal lobes during talking in schizophrenia. Biol Psychiatry 2002; 51: 485-492. (Pubitemid 34260970)
33. Tauscher J, Fischer P, Neumeister A, Rappelsberger P, Kasper S: Low frontal electroencephalographic coherence in neurolepticfree schizophrenic patients. Biol Psychiatry 1998; 44: 438-447. (Pubitemid 28451931)
34. Yeragani VK, Cashmere D, Miewald J, Tancer M, Keshavan MS: Decreased coherence in higher frequency ranges (beta and gamma) between central and frontal EEG in patients with schizophrenia: a preliminary report. Psychiatry Res 2006; 141: 53-60. (Pubitemid 43011350)
35. Higashima M, Takeda T, Kikuchi M, Nagasawa T, Hirao N, Oka T, Nakamura M, Koshino Y: State-dependent changes in intrahemispheric EEG coherence for patients with acute exacerbation of schizophrenia. Psychiatry Res 2007; 149: 41-47. (Pubitemid 46108089)
36. Nagase Y, Okubo Y, Matsuura M, Kojima T, Toru M: EEG coherence in unmedicated schizophrenic patients: topographical study of predominantly never medicated cases. Biol Psychiatry 1992; 32: 1028-1034. (Pubitemid 23026377)
37. Sebban C, Tesolin-Decros B, Ciprian-Ollivier J, Perret L, Spedding M: Effects of phencyclidine (PCP) and MK-801 on the EEGq in the prefrontal cortex of conscious rats: antagonism by clozapine, and antagonists of AMPA-, 1 - and 5-HT 2A -receptors. Br J Pharmacol 2002; 135: 65-78. (Pubitemid 34102099)
38. Pinault D: N -methyl- D -aspartate receptor antagonists ketamine and MK-801 induce wake-related aberrant gamma oscillations in the rat neocortex. Biol Psychiatry 2008; 63: 730-735. (Pubitemid 351400766)
39. Ma J, Shen B, Rajakumar N, Leung LS: The medial septum mediates impairment of prepulse inhibition of acoustic startle induced by a hippocampal seizure or phencyclidine. Behav Brain Res 2004; 155: 153-166. (Pubitemid 39119976)
40. Ma J, Leung LS: The supramammillo-septalhippocampal pathway mediates sensorimotor gating impairment and hyperlocomotion induced by MK-801 and ketamine in rats. Psychopharmacology (Berl) 2007; 191: 961-974. (Pubitemid 46399137)
41. Yang SY, Hong CJ, Huang YH, Tsai SJ: The effects of glycine transporter I inhibitor, N - methylglycine (sarcosine), on ketamine-induced alterations in sensorimotor gating and regional brain c-Fos expression in rats. Neurosci Lett 2010; 469: 127-130.
42. Imre G, Salomons A, Jongsma M, Fokkema DS, den Boer JA, ter Horst GJ: Effects of the mGluR2/3 agonist LY379268 on ketamineevoked behaviours and neurochemical changes in the dentate gyrus of the rat. Pharmacol Biochem Behav 2006; 84: 392-399. (Pubitemid 44292240)
43. Littlewood CL, Cash D, Dixon AL, Dix SL, White CT, O'Neill MJ, Tricklebank M, Williams SC: Using the BOLD MR signal to differentiate the stereoisomers of ketamine in the rat. Neuroimage 2006; 32: 1733-1746. (Pubitemid 44332281)
44. Littlewood CL, Jones N, O'Neill MJ, Mitchell SN, Tricklebank M, Williams SC: Mapping the central effects of ketamine in the rat using pharmacological MRI. Psychopharmacology (Berl) 2006; 186: 64-81. (Pubitemid 43668312)
45. Danysz W, Essmann U, Bresink I, Wilke R: Glutamate antagonists have different effects on spontaneous locomotor activity in rats. Pharmacol Biochem Behav 1994; 48: 111-118. (Pubitemid 24135163)
46. Fu Y, Guo L, Zhang J, Chen Y, Wang X, Zeng T, Tian S, Ma Y: Differential effects of ageing on the EEG during pentobarbital and ketamine anaesthesia. Eur J Anaesthesiol 2008; 25: 826-833.
47. Lu J, Nelson LE, Franks N, Maze M, Chamberlin NL, Saper CB: Role of endogenous sleep-wake and analgesic systems in anesthesia. J Comp Neurol 2008; 508: 648-662. (Pubitemid 351656390)
48. Pálenícek T, Fujáková M, Kutová M, Brunovsky M, Bubeníková-Valesová V, Horácek J: Quantitative EEG in three pharmacological models of psychosis (abstract). Eur Psychiatry 2008; 23:S136.
49. Pálenícek T, Fujáková M, Kutová M, Brunovsky M, Horácek J, Sos P, Tislerová B, Bubení ková-Valesová V: Quantitative EEG in glutamatergic and dopaminergic models of psychosis: animal study (abstract). Abstracts IPEG Meeting, Rouffach, 2008, pp 30-31.
50. Pálenícek T, Horácek J: The effect of ketamine on sensorimotor gating: comparison of human and animal data (abstract). Abstracts 9th World Congress of Biological Psychiatry, Paris, 2009, p 170.
51. Ebert B, Mikkelsen S, Thorkildsen C, Borgbjerg FM: Norketamine, the main metabolite of ketamine, is a non-competitive NMDA receptor antagonist in the rat cortex and spinal cord. Eur J Pharmacol 1997; 333: 99-104. (Pubitemid 27380456)
52. Pálenícek T, Votava M, Bubeníková V, Horácek J: Increased sensitivity to the acute effects of MDMA ('ecstasy') in female rats. Physiol Behav 2005; 86: 546-553. (Pubitemid 41586251)
53. Pálenícek T, Hlinák Z, Bubeníková- Valesová V, Novák T, Horácek J: Sex differences in the effects of N,N-diethyllysergamide (LSD) on behavioural activity and prepulse inhibition. Prog Neuropsychopharmacol Biol Psychiatry 2010; 34: 588-596.
54. Pálenícek T, Balíková M, Bubení ková-Valesová V, Horácek J: Mescaline effects on rat behavior and its time profile in serum and brain tissue after a single subcutaneous dose. Psychopharmacology (Berl) 2008; 196: 51-62.
55. Paxinos G, Watson C: The Rat Brain in Stereotaxic Coordinates, ed 4. New York, Elsevier Academic, 2003.
56. Principe JC, Smith JR: Design and implementation of linear phase FIR filters for biological signal processing. IEEE Trans Biomed Eng 1986; 33: 550-559.
57. Thatcher RW, Walker RA, Giudice S: Human cerebral hemispheres develop at different rates and ages. Science 1987; 236: 1110-1113. (Pubitemid 17113256)
58. Thatcher RW, Biver CJ, North DM: Quantitative EEG and the Frye and Daubert standards of admissibility. Clin Electroencephalogr 2003; 34: 39-53. (Pubitemid 36583132)
59. Geyer MA, Light RK, Rose GJ, Petersen LR, Horwitt DD, Adams LM, Hawkins RL: A characteristic effect of hallucinogens on investigatory responding in rats. Psychopharmacology (Berl) 1979; 65: 35-40. (Pubitemid 10222234)
60. Sagratella S, Pezzola A, Popoli P, Scotti de Carolis AS: Different capability of N -methyl- D -aspartate antagonists to elicit EEG and behavioural phencyclidine-like effects in rats. Psychopharmacology (Berl) 1992; 109: 277-282.
61. Popoli P, Pezzola A, Sagratella S: Diphenylhydantoin potentiates the EEG and behavioural effects induced by N -methyl- D -aspartate antagonists in rats. Psychopharmacology (Berl) 1994; 113: 471-475. (Pubitemid 24150496)
62. Mattia A, Marquis KL, Leccese AP, El-Fakahany EE, Moreton JE: Electroencephalographic, behavioral and receptor binding correlates of phencyclinoids in the rat. J Pharmacol Exp Ther 1988; 246: 797-802.
63. Mattia A, Moreton JE: Electroencephalographic (EEG), EEG power spectra, and behavioral correlates in rats given phencyclidine. Neuropharmacology 1986; 25: 763-769. (Pubitemid 16067177)
64. Marquis KL, Paquette NC, Gussio RP, Moreton JE: Comparative electroencephalographic and behavioral effects of phencyclidine, (+)-SKF-10,047 and MK-801 in rats. J Pharmacol Exp Ther 1989; 251: 1104-1112. (Pubitemid 20024931)
65. Marquis KL, Gussio R, Webb MG, Moreton JE: Cortical EEG changes during the self-administration of phencyclinoids. Neuropharmacology 1989; 28: 1193-1198. (Pubitemid 19277032)
66. Feinberg I, Campbell IG: Haloperidol potentiates the EEG slowing of MK-801 despite blocking its motor effects: implications for the PCP model of schizophrenia. Neuroreport 1998; 9: 2189-2193. (Pubitemid 28338204)
67. Pálenícek T, Fujáková M, Kutová M, Brunovsky M, Horácek J, Bubeníková-Valesová V: Behavioral and QEEG effects of the psychedelic drug 4-bromo-2,5- dimethoxyphenylethylamine (2C-B) in rats: a possible model of psychosis? (Abstract). Behav Pharmacol 2007; 18:S13.
68. Ma J, Leung LS: Relation between hippocampal gamma waves and behavioral disturbances induced by phencyclidine and methamphetamine. Behav Brain Res 2000; 111: 1-11. (Pubitemid 30326697)
69. Hakami T, Jones NC, Tolmacheva EA, Gaudias J, Chaumont J, Salzberg M, O'Brien TJ, Pinault D: NMDA receptor hypofunction leads to generalized and persistent aberrant gamma oscillations independent of hyperlocomotion and the state of consciousness. PLoS One 2009; 4:e6755.
70. Dimpfel W, Spuler M: Dizocilpine (MK-801), ketamine and phencyclidine: low doses affect brain field potentials in the freely moving rat in the same way as activation of dopaminergic transmission. Psychopharmacology (Berl) 1990; 101: 317-323. (Pubitemid 20193368)
71. Ehrlichman RS, Gandal MJ, Maxwell CR, Lazarewicz MT, Finkel LH, Contreras D, Turetsky BI, Siegel SJ: N -methyl- D -aspartic acid receptor antagonist-induced frequency oscillations in mice recreate pattern of electrophysiological deficits in schizophrenia. Neuroscience 2009; 158: 705-712.
72. Lazarewicz MT, Ehrlichman RS, Maxwell CR, Gandal MJ, Finkel LH, Siegel SJ: Ketamine modulates theta and gamma oscillations. J Cogn Neurosci 2010; 22: 1452-1464.
73. Holschneider DP, Leuchter AF, Scremin OU, Treiman DM, Walton NY: Effects of cholinergic deafferentation and NGF on brain electrical coherence. Brain Res Bull 1998; 45: 531-541. (Pubitemid 28188546)
74. Holschneider DP, Leuchter AF, Walton NY, Scremin OU, Treiman DM: Changes in cortical EEG and cholinergic function in response to NGF in rats with nucleus basalis lesions. Brain Res 1997; 765: 228-237. (Pubitemid 27397618)
75. Vyazovskiy V, Achermann P, Borbély AA, Tobler I: Interhemispheric coherence of the sleep electroencephalogram in mice with congenital callosal dysgenesis. Neuroscience 2004; 124: 481-488. (Pubitemid 38229667)
76. Maloney KJ, Cape EG, Gotman J, Jones BE: High-frequency gamma electroencephalogram activity in association with sleep-wake states and spontaneous behaviors in the rat. Neuroscience 1997; 76: 541-555. (Pubitemid 27008483)
77. Vyazovskiy VV, Tobler I, Winsky-Sommerer R: Alteration of behavior in mice by muscimol is associated with regional electroencephalogram synchronization. Neuroscience 2007; 147: 833-841. (Pubitemid 46990658)
78. Lisman J, Buzsaki G: A neural coding scheme formed by the combined function of gamma and theta oscillations. Schizophr Bull 2008; 34: 974-980.
79. Niedermeyer E, Lopes da Silva F: Electroencephalography. Basic Principles, Clinical Applications, and Related Fields, ed 5. Philadelphia, Lippincott Williams & Wilkins, 2004.
80. Hoffman RE, Buchsbaum MS, Escobar MD, Makuch RW, Nuechterlein KH, Guich SM: EEG coherence of prefrontal areas in normal and schizophrenic males during perceptual activation. J Neuropsychiatry Clin Neurosci 1991; 3: 169-175.
81. Merrin EL, Floyd TC: Negative symptoms and EEG alpha activity in schizophrenic patients. Schizophr Res 1992; 8: 11-20.
82. Norman RM, Malla AK, Williamson PC, Morrison-Stewart SL, Helmes E, Cortese L: EEG coherence and syndromes in schizophrenia. Br J Psychiatry 1997; 170: 411-415. (Pubitemid 27224535)
83. Krishnan GP, Hetrick WP, Brenner CA, Shekhar A, Steffen AN, O'Donnell BF: Steady state and induced auditory gamma deficits in schizophrenia. Neuroimage 2009; 47: 1711-1719.
84. Basar-Eroglu C, Schmiedt-Fehr C, Mathes B, Zimmermann J, Brand A: Are oscillatory brain responses generally reduced in schizophrenia during long sustained attentional processing? Int J Psychophysiol 2009; 71: 75-83.
85. Roach BJ, Mathalon DH: Event-related EEG time-frequency analysis: an overview of measures and an analysis of early gamma band phase locking in schizophrenia. Schizophr Bull 2008; 34: 907-926.
86. Siegle GJ, Condray R, Thase ME, Keshavan M, Steinhauer SR: Sustained gamma-band EEG following negative words in depression and schizophrenia. Int J Psychophysiol 2010; 75: 107-118.
87. Pálenícek T, Brunovsky M, Horácek J, Fujáková M, Gorman I, Tyls F, Krajca V: The effect of ketamine on sensorimotor gating, EEG spectra and coherence: comparison of human and animal data (abstract). Int J Neuropsychopharmacol 2010; 13: 231-232.
88. Horácek J, Bubeníková-Valesová V, Kopecek M, Pálenícek T, Dockery C, Mohr P, Höschl C: Mechanism of action of atypical antipsychotic drugs and the neurobiology of schizophrenia. CNS Drugs 2006; 20: 389-409. (Pubitemid 43763739)
89. Horácek J, Brunovsky M, Novák T, Tislerová B, Pálenícek T, Bubeníková-Valesová V, Spaniel F, Koprivová J, Mohr P, Balíková M, Höschl C: Subanesthetic dose of ketamine decreases prefrontal theta cordance in healthy volunteers: implications for antidepressant effect. Psychol Med 2010; 40: 1443-1451.
90. Fujáková M, Pálenícek T, Brunovsky M, Gorman I, Horácek J, Bubeníková-Valesová V, Krajca V: The effect of metabotropic glutamate mGlu2/3 receptor agonist (LY379268) on quantitative EEG in ketamine model of psychosis: an animal study (abstract; in Polish). Psychiatrie 2010; 14: 42.